Cell Bio Human Tech KRX:318160KOSDAQ
셀바이오휴먼텍 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked3since Sep 11
In Q2 2026, Cell Bio Human Tech reported revenue of ₩19.4bn, up 38.4% year on year, and operating profit of ₩3.5bn. Cell Bio Human Tech (셀바이오휴먼텍) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 21 with 1 article. The most common catalyst was stakes & m&a (1).
Filing signals Revenue +30% Revenue & profit growth Screener
Cell Bio Human Tech quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩19.4bn | +38.4% | ₩3.5bn margin 18.0% | ₩2.9bn |
| Q1 2026 | ₩12.7bn | +53.8% | ₩1.5bn margin 11.4% | ₩1.8bn |
| Q4 2025 derived | ₩14.3bn | +72.7% | ₩1.2bn margin 8.5% | ₩2.2bn |
| Q3 2025 | ₩14.5bn | +105.3% | ₩3.6bn margin 24.9% | ₩3.5bn |
| Q2 2025 | ₩14.0bn | +96.2% | ₩3.0bn margin 21.6% | ₩1.6bn |
| Q1 2025 | ₩8.3bn | +39.2% | ₩1.5bn margin 17.7% | ₩1.4bn |
| Q4 2024 derived | ₩8.3bn | +7.9% | ₩1.3bn margin 15.7% | ₩2.0bn |
| Q3 2024 | ₩7.1bn | -0.3% | ₩1.2bn margin 16.7% | ₩955m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Cell Bio Human Tech top stories 2 weeks, by number of outlets
- 1